Becton, Dickinson and Company (BDX)
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
BDX's Revello stent shows strong nine-month AGILITY trial results, with high vessel patency and low failure rates, boosting its peripheral vascular prospects.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BDX Expands U.S. Manufacturing With $19B Healthcare Investment
BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve
Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.
BDX Deploys Vmax 160 to Advance Intelligent Pharmacy Automation
BD expands U.S. pharmacy automation with Vmax 160 at Fairview to handle complex specialty and refrigerated medications.
BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study
BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention.
Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH
Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week.
Becton, Dickinson and Company Q3 Earnings Call Highlights
Becton, Dickinson and Company NYSE: BDX reported third-quarter fiscal 2026 revenue of $5 billion, up 4.4% on an FX-neutral basis, as growth across its key platforms and operational productivity helped results exceed the company's expectations.
BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down
BDX tops third-quarter fiscal 2026 earnings and revenue estimates as broad segment growth offset pressure on gross and operating margins.
Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript
Becton, Dickinson and Company (BDX) Q3 2026 Earnings Call Transcript
Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Becton Dickinson (BDX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates
Becton Dickinson (BDX) came out with quarterly earnings of $3.23 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $3.68 per share a year ago.
